Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]
Discontinued
Reference number: GID-TA10567
Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late-October 2021 when we will write to you about how you can get involved.
These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.